UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): April 14, 2008
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
2
Elza Street
Jerusalem,
Israel 93706
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-54-790-9058
_____________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE.
|
On
April
14, 2008, the registrant issued a press release announcing that it has commenced
Phase 2A studies of its oral insulin on diabetic volunteers. A copy of the
press
release is attached to this Current Report on Form 8-K as Exhibit 99.1 and
is
incorporated herein by reference.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(c)
|
Exhibits
|
|
|
99.1
|
Press
Release, dated April 14, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
Dated:
April 14, 2008
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
Nadav
Kidron
|
|
|
|
President,
CEO and Director
|
2
Oramed
Pharmaceuticals Commences Phase 2A Clinical Trials in
Israel
Oramed
Begins Studies on its Oral Insulin Capsule at Hadassah Medical
Center
JERUSALEM,
Israel - April 14, 2008 - Oramed Pharmaceuticals, Inc., (OTCBB: ORMP,
www.oramed.com), a developer of oral delivery systems, commenced Phase 2A
studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem,
Israel yesterday. The Phase 2A trial is focused on assessing the safety and
efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study
is a continuation of the recently successfully completed Phase 1 studies in
Israel.
“We
are
pleased to have achieved this milestone of beginning Phase 2A clinical trials
in
Israel in the second quarter of this year,” said Nadav Kidron, CEO of Oramed
Pharmaceuticals. “We have had much success with our past clinical trials, and
are on schedule with reaching our planned milestones and hope that Oramed’s oral
insulin capsule will succeed in revolutionizing the current treatment for
diabetes.”
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is an Israeli-based company focused on the development of oral
delivery solutions based on proprietary technology. Diabetes is one of the
most
rapidly growing diseases in the world and is one that requires constant and
often unpleasant monitoring and drug therapy regimens. Oramed is currently
developing an orally ingestible insulin capsule for the treatment of diabetes.
The company is also pursuing the development of oral delivery solutions for
other drugs and vaccines.
For
more
information please visit our website at: www.oramed.com.
Forward-looking
statements
Some
of
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company’s ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company’s filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
Contact:
Oramed
Pharmaceuticals, Inc
Investor
Relations:
Erika
Moran, Salima Rasul
Public
Relations:
Lynn
Granito, Steven Melfi
212-825-3210
info@oramed.com
www.oramed.com